...
首页> 外文期刊>Heart failure reviews >Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials
【24h】

Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials

机译:呋塞米和其他利尿剂在心力衰竭治疗中的比较效果:随机对照试验的系统回顾与荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Diuretics have an essential role in the management of heart failure (HF). However, each drug has its own benefit and side effect. Side effects include fluid, electrolyte abnormalities, and acid-base disturbance. These adverse effects of diuretics predispose patients to serious cardiac arrhythmias and may increase the risk of arrhythmic mortality. Herein, we aim to summarize the relative efficacy and safety of all available diuretics used in the treatment of patients with HF. In June 2017, a systematic electronic database search was conducted in nine databases. All randomized controlled trials (RCTs) comparing the different diuretics used in HF were included for meta-analysis. The protocol was registered in Prospero with CRD42018084819. Among the included 54 studies (10,740 patients), 34 RCTs were eligible for quantitative network meta-analysis (NMA) and traditional meta-analysis while the other 20 studies were qualitatively analyzed. Our results showed that azosemide and torasemide caused a significant reduction in brain natriuretic peptide (BNP) level. Torasemide also caused a significant decrease in collagen volume fraction (CVF) and edema. No significant difference between the agents concerning glomerular filtration rate (GFR), water extraction, and sodium excretion was demonstrated. Regarding side effects, no significant difference among diuretics was observed in terms of hospital readmission and mortality rates. Diuretics are the main treatment of hypervolemia in HF patients. The choice of appropriate diuretic is essential for successful management and is mainly guided by patient clinical situations and the presence of other co-morbidities.
机译:利尿剂在心力衰竭(HF)的治疗中起着至关重要的作用。然而,每种药物都有其自身的益处和副作用。副作用包括体液、电解质异常和酸碱紊乱。利尿剂的这些副作用使患者易患严重心律失常,并可能增加心律失常死亡的风险。在此,我们旨在总结所有可用利尿剂治疗心衰患者的相对有效性和安全性。2017年6月,在九个数据库中进行了系统的电子数据库搜索。所有比较心衰不同利尿剂的随机对照试验(RCT)均纳入荟萃分析。该方案在Prospero注册,注册号为CRD42018084819。在纳入的54项研究(10740名患者)中,34项随机对照试验符合定量网络荟萃分析(NMA)和传统荟萃分析的条件,而其他20项研究则进行了定性分析。我们的研究结果表明,偶氮塞米和托拉塞米导致脑钠肽(BNP)水平显著降低。托拉塞米还能显著降低胶原体积分数(CVF)和水肿。两种药物在肾小球滤过率(GFR)、水提取率和钠排泄率方面没有显著差异。关于副作用,在再次住院和死亡率方面,利尿剂之间没有观察到显著差异。利尿剂是心力衰竭患者高血容量的主要治疗方法。选择合适的利尿剂是成功治疗的关键,主要取决于患者的临床情况和其他合并症的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号